Biodexa Pharmaceuticals (BDRX) Competitors $0.87 -0.01 (-1.59%) Closing price 07/3/2025 03:26 PM EasternExtended Trading$0.87 0.00 (0.00%) As of 07/3/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock BDRX vs. NKTX, FTLF, CRBU, IKT, CTNM, RAPT, GLSI, TARA, THTX, and BHSTShould you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include Nkarta (NKTX), FitLife Brands (FTLF), Caribou Biosciences (CRBU), Inhibikase Therapeutics (IKT), Contineum Therapeutics (CTNM), Rapt Therapeutics (RAPT), Greenwich LifeSciences (GLSI), Protara Therapeutics (TARA), Theratechnologies (THTX), and BioHarvest Sciences (BHST). These companies are all part of the "pharmaceutical products" industry. Biodexa Pharmaceuticals vs. Its Competitors Nkarta FitLife Brands Caribou Biosciences Inhibikase Therapeutics Contineum Therapeutics Rapt Therapeutics Greenwich LifeSciences Protara Therapeutics Theratechnologies BioHarvest Sciences Biodexa Pharmaceuticals (NASDAQ:BDRX) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk. Do institutionals & insiders have more ownership in BDRX or NKTX? 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Comparatively, 8.4% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings and valuation, BDRX or NKTX? Biodexa Pharmaceuticals has higher revenue and earnings than Nkarta. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiodexa Pharmaceuticals$470K67.33-$7.32MN/AN/ANkartaN/AN/A-$108.79M-$1.51-1.16 Is BDRX or NKTX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Nkarta's return on equity.Company Net Margins Return on Equity Return on Assets Biodexa PharmaceuticalsN/A N/A N/A Nkarta N/A -26.64%-21.62% Do analysts recommend BDRX or NKTX? Nkarta has a consensus price target of $14.33, indicating a potential upside of 716.71%. Given Nkarta's stronger consensus rating and higher possible upside, analysts plainly believe Nkarta is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Nkarta 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13 Which has more risk & volatility, BDRX or NKTX? Biodexa Pharmaceuticals has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Does the media refer more to BDRX or NKTX? In the previous week, Biodexa Pharmaceuticals and Biodexa Pharmaceuticals both had 3 articles in the media. Nkarta's average media sentiment score of 0.25 beat Biodexa Pharmaceuticals' score of 0.23 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodexa Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nkarta 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryNkarta beats Biodexa Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDRX vs. The Competition Export to ExcelMetricBiodexa PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.16M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.09%P/E RatioN/A21.5627.4020.24Price / Sales67.33277.33417.66125.07Price / CashN/A41.9536.6357.47Price / Book2.997.518.085.67Net Income-$7.32M-$55.05M$3.16B$248.47M7 Day Performance-0.46%4.59%2.81%3.29%1 Month Performance-25.34%4.86%3.69%5.18%1 Year PerformanceN/A5.82%35.30%21.35% Biodexa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDRXBiodexa Pharmaceuticals0.602 of 5 stars$0.87-1.6%N/AN/A$32.16M$470K0.0020Upcoming EarningsNKTXNkarta2.2867 of 5 stars$1.75-1.4%$14.33+721.4%-67.2%$125.60MN/A-1.16140FTLFFitLife Brands4.0733 of 5 stars$12.99-2.5%$20.50+57.8%-7.3%$125.09M$64.47M15.4620CRBUCaribou Biosciences2.3387 of 5 stars$1.32-1.5%$8.50+543.9%-15.0%$124.63M$9.99M-0.81100News CoverageIKTInhibikase Therapeutics1.414 of 5 stars$1.66flat$6.50+291.6%+64.3%$123.41M$260K-0.626News CoverageCTNMContineum Therapeutics2.2215 of 5 stars$4.12-13.4%$22.50+446.1%-80.2%$123.15M$50M-2.0931High Trading VolumeRAPTRapt Therapeutics4.3632 of 5 stars$7.44+0.1%$24.00+222.6%-62.7%$122.86M$1.53M-0.3980GLSIGreenwich LifeSciences1.5297 of 5 stars$8.76-1.6%$39.00+345.2%-39.9%$118.98MN/A-6.953TARAProtara Therapeutics1.7636 of 5 stars$2.88-5.6%$20.50+611.8%+38.4%$117.68MN/A-1.6730THTXTheratechnologiesN/A$2.46-2.8%N/A+131.9%$116.33M$85.87M-30.75140News CoverageUpcoming EarningsAnalyst ForecastGap UpBHSTBioHarvest SciencesN/A$6.83-3.3%$13.67+100.1%N/A$115.98M$25.19M-13.66N/A Related Companies and Tools Related Companies Nkarta Competitors FitLife Brands Competitors Caribou Biosciences Competitors Inhibikase Therapeutics Competitors Contineum Therapeutics Competitors Rapt Therapeutics Competitors Greenwich LifeSciences Competitors Protara Therapeutics Competitors Theratechnologies Competitors BioHarvest Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDRX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals PLC Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BDRX Stock Alerts